Summary
The pharmacokinetics of prazosin (Minipress®) were studied in nine patients with NYHA Class 3 or 4 congestive heart failure and in five healthy controls. After a single 5 mg oral dose, plasma concentrations of prazosin, as reflected in the area under the plasma concentration-time curve (AUC) and prazosin plasma half-life, were approximately double in the patients in comparison to the control group. Reduction in hepatic blood flow, altered gastrointestinal absorption of the drug or diminished intrinsic hepatic metabolic activity in the patient group may have contributed to the observed changes in prazosin disposition. The finding of higher prazosin plasma concentrations in patients with refractory heart failure demonstrates the need for close monitoring of these individuals following administration of the drug in the treatment of chronic congestive heart failure.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bolli P, Wood AJ, Phelan EL, Lee DR, Simpson, FO (1975) Prazosin: preliminary clinical and pharmacological observation. Clin Sci Mol Med 48: 177s
Oates HF, Graham RM, Stoker LM, Stokes GS (1976) Haemodynamic effects of prazosin. Arch Int Pharmacodyn Ther 244: 239–274
Oates HF, Graham RM, Stokes GS (1977) Mechanism of the hypotensive action of prazosin. Arch Int Pharmacodyn Ther 227: 41–48
Awan NA, Miller RR, DeMaria AN, Maxwell KS, Neumann A, Mason DT (1977) Efficacy of ambulatory vasodilator therapy with oral prazosin in chronic refractory heart failure: Concomitant relief of pulmonary congestion and elevation of pump output demonstrated by improvements in symptomatology, exercise tolerance, hemodynamics and echocardiography. Circulation 56: 346
Miller RR, Awan NA, Maxwell KS, Mason DT (1977) Sustained reduction of cardiac impedance and preload in congestive heart failure with the antihypertensive vasodilator prazosin. N Engl J Med 297: 303–307
Collins IS, Pek P (1975) Pharmacokinetics of prazosin, a new antihypertensive compound. Clin Exp Pharmacol Physiol 2: 445
Brogden RM, Heel RC, Speight TM, Avery GS (1977) Prazosin: a review of its pharmacological properties and therapeutic efficacy in hypertension. Drugs 14: 163–197
Bateman DN, Hobbs DC, Twomey TM, Stevens EA, Rawlins MD (1979) Prazosin, pharmacokinetics and concentration effect. Eur J Clin Pharmacol 16: 171–181
Benowitz NL, Meister W (1976) Pharmacokinetics in patients with cardiac failure. Clin Pharmacokinet 1: 389–405
Dunn GD, Hayes P, Breen KJ, Schenker S (1973) The liver in congestive heart failure: Am J Med Sci 265: 174–189
Lin ET, Baughman RA, Benet LZ (in press 1980) HPLC determination of prazosin hydrochloride in human plasma, whole blood and urine. J Chromatogr
Yeh KC, Kwan KC (1978) A comparison of numerical integrating algorithms by trapezoidal, Lagrange and spline approximation. J Pharmacokinet Biopharm 6: 79–98
Gibaldi M, Perrier D (1975) Pharmacokinetics. Marcel Dekker, New York, p 151
Jaillon P, Rubin P, Yee YG, Kates R, Blaschke T, Harrison DC (1979) Influence of congestive heart failure on prazosin kinetics. Clin Pharmacol Ther 25: 790–794
Rowland M, Benet LZ, Graham GG (1973) Clearance concepts in pharmacokinetics. J Pharmacokinet Biopharm 1: 123–136
Graham RM, Thornell IR, Gain JM, Bagnoli C, Oates HF, Stokes GS (1976) Prazosin: the first-dose phenomenon. Br Med J 2: 1293–1294
Author information
Authors and Affiliations
Additional information
Sponsored by the National Institute of General Medical Sciences Training Grant GM 07546 and by a grant from Pfizer Corporation
Rights and permissions
About this article
Cite this article
Baughman, R.A., Arnold, S., Benet, L.Z. et al. Altered prazosin pharmacokinetics in congestive heart failure. Eur J Clin Pharmacol 17, 425–428 (1980). https://doi.org/10.1007/BF00570159
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00570159